Deze website maakt gebruik van cookies. We gebruiken cookies om instellingen te onthouden en je bezoek soepeler te laten verlopen. Daarnaast gebruiken we ook cookies voor de verbetering van de website en het verzamelen en analyseren van statistieken. Lees meer over cookies

Home
Anja Krippner-Heidenreich

Anja Krippner-Heidenreich

Senior onderzoeker

Heidenreich groep

Anja is senior onderzoeker in de groep van Olaf Heidenreich.

Telefoon +31 65000 6430

E-mail a.krippner@prinsesmaximacentrum.nl

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML
- apr. 2024
- Vania, Lo Presti, et al
- Journal for ImmunoTherapy of Cancer
Acute myeloid leukemias with UBTF tandem duplications are sensitive to Menin inhibitors
- okt. 2023
- Juan Martin, Barajas, et al
- Blood
Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles
- mei 2023
- Laura E, Swart, et al
- Pharmaceutics
Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia
- apr. 2021
- Yuzhe, Shi, et al
- Haematologica
TNF-α–induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade–driven IL-17A expression
- aug. 2018
- Paulo C.M., Urbano, et al
- Journal of Allergy and Clinical Immunology

Bekijk alle publicaties

Anja Krippner-Heidenreich

Publicaties

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

Acute myeloid leukemias with UBTF tandem duplications are sensitive to Menin inhibitors

Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles

Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia

TNF-α–induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade–driven IL-17A expression